Trade Dominari Holdings Inc. - DOMH CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 2.32 |
Open* | 2.36 |
1-Year Change* | -65.29% |
Day's Range* | 2.29 - 2.36 |
52 wk Range | 2.06-7.27 |
Average Volume (10 days) | 6,030.00 |
Average Volume (3 months) | 232.55K |
Market Cap | 14.49M |
P/E Ratio | -100.00K |
Shares Outstanding | 5.35M |
Revenue | 71.00K |
EPS | -4.99 |
Dividend (Yield %) | N/A |
Beta | 0.97 |
Next Earnings Date | Nov 15, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 3, 2023 | 2.31 | -0.04 | -1.70% | 2.35 | 2.36 | 2.29 |
Oct 2, 2023 | 2.32 | 0.02 | 0.87% | 2.30 | 2.32 | 2.30 |
Sep 29, 2023 | 2.35 | 0.01 | 0.43% | 2.34 | 2.35 | 2.34 |
Sep 28, 2023 | 2.35 | 0.06 | 2.62% | 2.29 | 2.41 | 2.29 |
Sep 27, 2023 | 2.38 | -0.01 | -0.42% | 2.39 | 2.45 | 2.31 |
Sep 26, 2023 | 2.35 | 0.07 | 3.07% | 2.28 | 2.35 | 2.28 |
Sep 25, 2023 | 2.30 | -0.14 | -5.74% | 2.44 | 2.44 | 2.27 |
Sep 22, 2023 | 2.40 | -0.05 | -2.04% | 2.45 | 2.45 | 2.40 |
Sep 21, 2023 | 2.44 | -0.08 | -3.17% | 2.52 | 2.52 | 2.44 |
Sep 20, 2023 | 2.54 | 0.15 | 6.28% | 2.39 | 2.86 | 2.39 |
Sep 19, 2023 | 2.45 | 0.05 | 2.08% | 2.40 | 2.49 | 2.34 |
Sep 18, 2023 | 2.54 | -0.15 | -5.58% | 2.69 | 2.69 | 2.54 |
Sep 15, 2023 | 2.64 | -0.05 | -1.86% | 2.69 | 2.69 | 2.64 |
Sep 14, 2023 | 2.59 | -0.01 | -0.38% | 2.60 | 2.73 | 2.55 |
Sep 13, 2023 | 2.63 | -0.03 | -1.13% | 2.66 | 2.73 | 2.61 |
Sep 12, 2023 | 2.69 | 0.03 | 1.13% | 2.66 | 2.70 | 2.66 |
Sep 11, 2023 | 2.69 | 0.00 | 0.00% | 2.69 | 2.74 | 2.69 |
Sep 8, 2023 | 2.69 | 0.01 | 0.37% | 2.68 | 2.70 | 2.68 |
Sep 7, 2023 | 2.70 | -0.03 | -1.10% | 2.73 | 2.74 | 2.70 |
Sep 6, 2023 | 2.57 | 0.00 | 0.00% | 2.57 | 2.57 | 2.57 |
Dominari Holdings Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, November 15, 2023 | ||
Time (UTC) 21:00 | Country US
| Event Q3 2023 Aikido Pharma Inc Earnings Release Q3 2023 Aikido Pharma Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0.009 | 0.028 |
Revenue | 0 | 0.009 | 0.028 | ||
Total Operating Expense | 14.346 | 9.441 | 6.546 | 5.694 | 6.902 |
Selling/General/Admin. Expenses, Total | 11.683 | 7.734 | 4.057 | 3.172 | 3.056 |
Depreciation / Amortization | 1.443 | ||||
Unusual Expense (Income) | 0 | 2.403 | |||
Operating Income | -14.346 | -9.441 | -6.546 | -5.685 | -6.874 |
Interest Income (Expense), Net Non-Operating | -7.825 | 2.135 | -5.81 | 1.502 | 8.601 |
Net Income Before Taxes | -22.107 | -7.171 | -12.337 | -4.183 | 1.727 |
Net Income After Taxes | -22.107 | -7.171 | -12.337 | -4.183 | 1.727 |
Net Income Before Extra. Items | -22.107 | -7.171 | -12.337 | -4.183 | 1.727 |
Net Income | -22.107 | -7.171 | -12.337 | -4.183 | 1.727 |
Total Adjustments to Net Income | -4.109 | ||||
Income Available to Common Excl. Extra. Items | -26.216 | -7.171 | -12.337 | -4.183 | 1.727 |
Income Available to Common Incl. Extra. Items | -26.216 | -7.171 | -12.337 | -4.183 | 1.727 |
Diluted Net Income | -26.216 | -7.171 | -12.337 | -4.183 | 1.727 |
Diluted Weighted Average Shares | 5.33408 | 4.84667 | 1.65142 | 0.14773 | 0.11157 |
Diluted EPS Excluding Extraordinary Items | -4.91482 | -1.47957 | -7.47055 | -28.3151 | 15.4797 |
Diluted Normalized EPS | -4.91482 | -1.47957 | -7.47055 | -28.3151 | 37.0186 |
Total Extraordinary Items | |||||
Research & Development | 2.663 | 1.707 | 2.489 | 2.522 | |
Other, Net | 0.064 | 0.135 | 0.019 | ||
Dividends per Share - Common Stock Primary Issue | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0.071 | 0 | 0 | 0 | 0 |
Total Operating Expense | 9.082 | 3.834 | 3.144 | 5.101 | 2.298 |
Selling/General/Admin. Expenses, Total | 9.08 | 3.833 | 3.119 | 4.515 | 2.262 |
Research & Development | 0.002 | 0.001 | 0.025 | 0.586 | 0.036 |
Operating Income | -9.011 | -3.834 | -3.144 | -5.101 | -2.298 |
Interest Income (Expense), Net Non-Operating | 0.56 | 0.072 | -4.112 | -1.138 | -2.779 |
Other, Net | -0.212 | 0 | 0 | 0 | 0 |
Net Income Before Taxes | -8.663 | -3.762 | -7.256 | -6.239 | -5.077 |
Net Income After Taxes | -8.663 | -3.762 | -7.256 | -6.239 | -5.077 |
Net Income Before Extra. Items | -8.663 | -3.762 | -7.256 | -6.239 | -5.077 |
Net Income | -8.663 | -3.762 | -7.256 | -6.239 | -5.077 |
Income Available to Common Excl. Extra. Items | -8.663 | -3.762 | -7.256 | -6.239 | -6.177 |
Income Available to Common Incl. Extra. Items | -8.663 | -3.762 | -7.256 | -6.239 | -6.177 |
Diluted Net Income | -8.663 | -3.762 | -7.256 | -6.239 | -6.177 |
Diluted Weighted Average Shares | 4.82724 | 5.30551 | 5.48675 | 5.34499 | 5.25102 |
Diluted EPS Excluding Extraordinary Items | -1.79461 | -0.70907 | -1.32246 | -1.16726 | -1.17634 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.79461 | -0.70907 | -1.32246 | -1.16726 | -1.17634 |
Total Adjustments to Net Income | 0 | 0 | 0 | 0 | -1.1 |
Revenue | 0.071 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 50.656 | 90.889 | 27.731 | 1.129 | 2.905 |
Cash and Short Term Investments | 42.317 | 83.463 | 27.516 | 0.948 | 2.717 |
Cash & Equivalents | 0.091 | 0.017 | |||
Short Term Investments | 9.143 | 13.7 | 24.801 | 0.857 | 2.7 |
Prepaid Expenses | 0.865 | 0.442 | 0.215 | 0.181 | 0.188 |
Total Assets | 76.236 | 102.656 | 30.495 | 11.282 | 13.251 |
Property/Plant/Equipment, Total - Net | 0.919 | 0 | 0.001 | ||
Intangibles, Net | 0 | ||||
Other Long Term Assets, Total | 0.458 | 0.155 | 0 | ||
Total Current Liabilities | 1.789 | 1.061 | 0.877 | 0.75 | 1.153 |
Payable/Accrued | 0.447 | 0.381 | 0.567 | 0.068 | 0.132 |
Accrued Expenses | 1.342 | 0.68 | 0.31 | 0.682 | 0.732 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | ||||
Other Current Liabilities, Total | 0 | 0.289 | |||
Total Liabilities | 2.469 | 1.061 | 0.877 | 0.75 | 1.153 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | |||||
Other Liabilities, Total | 0.68 | 0 | |||
Total Equity | 73.767 | 101.595 | 29.618 | 10.532 | 12.098 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.00055 | 0.009 | 0.003 | 0 | 0.001 |
Additional Paid-In Capital | 262.97 | 265.624 | 186.482 | 155.062 | 152.444 |
Retained Earnings (Accumulated Deficit) | -185.881 | -163.774 | -156.603 | -144.266 | -140.083 |
Treasury Stock - Common | -3.322 | -0.264 | -0.264 | -0.264 | -0.264 |
Total Liabilities & Shareholders’ Equity | 76.236 | 102.656 | 30.495 | 11.282 | 13.251 |
Total Common Shares Outstanding | 5.01708 | 5.27505 | 2.05401 | 0.28384 | 0.11823 |
Total Preferred Shares Outstanding | 0.00466 | 0.00466 | 0.00556 | 0.00556 | 0.00556 |
Long Term Investments | 23.103 | 9.465 | 2.764 | 10.153 | 10.345 |
Cash | 33.174 | 69.763 | 2.715 | ||
Total Receivables, Net | 7.474 | 6.984 | |||
Accounts Receivable - Trade, Net | 7.474 | 6.984 | |||
Note Receivable - Long Term | 1.1 | 2.147 | |||
Other Equity, Total | -0.00055 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 44.771 | 50.656 | 56.092 | 61.563 | 99.181 |
Cash and Short Term Investments | 33.94 | 42.317 | 46.754 | 52.867 | 68.57 |
Cash & Equivalents | 38.791 | ||||
Short Term Investments | 24.407 | 9.143 | 8.065 | 9.883 | 14.69 |
Prepaid Expenses | 0.745 | 0.865 | 0.693 | 0.196 | 0.348 |
Total Assets | 74.154 | 76.236 | 84.447 | 88.296 | 117.946 |
Long Term Investments | 23.103 | 23.103 | 26.089 | 25.478 | 18.61 |
Note Receivable - Long Term | 1.85 | 1.1 | 1.1 | 1.1 | 0 |
Total Current Liabilities | 1.72 | 1.789 | 1.899 | 0.829 | 0.895 |
Payable/Accrued | 0.641 | 0.447 | 0.518 | 0.142 | 0.209 |
Accrued Expenses | 0.955 | 1.342 | 1.381 | 0.687 | 0.686 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5.083 | 2.469 | 2.6 | 0.829 | 0.895 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 69.071 | 73.767 | 81.847 | 87.467 | 117.051 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 22 |
Common Stock | 0.00048 | 0.00055 | 0.00055 | 0.00052 | 0.009 |
Additional Paid-In Capital | 259.215 | 262.97 | 262.973 | 261.603 | 262.615 |
Retained Earnings (Accumulated Deficit) | -189.643 | -185.881 | -178.625 | -172.386 | -167.309 |
Treasury Stock - Common | -0.501 | -3.322 | -2.501 | -1.75 | -0.264 |
Total Liabilities & Shareholders’ Equity | 74.154 | 76.236 | 84.447 | 88.296 | 117.946 |
Total Common Shares Outstanding | 4.75545 | 5.01708 | 5.14011 | 5.00395 | 5.25224 |
Total Preferred Shares Outstanding | 0.00466 | 0.00466 | 0.00466 | 0.00466 | 0.00466 |
Cash | 9.533 | 33.174 | 38.689 | 4.193 | 53.88 |
Total Receivables, Net | 6.536 | 7.474 | 8.645 | 8.5 | 9.31 |
Accounts Receivable - Trade, Net | 6.536 | 7.474 | 8.645 | 8.5 | 9.31 |
Other Long Term Assets, Total | 0.458 | 0.458 | 0.458 | 0.155 | 0.155 |
Other Current Assets, Total | 3.55 | 20.953 | |||
Other Equity, Total | -0.00048 | -0.00055 | -0.00055 | -0.00052 | |
Property/Plant/Equipment, Total - Net | 3.972 | 0.919 | 0.708 | ||
Other Liabilities, Total | 3.363 | 0.68 | 0.701 | ||
Other Current Liabilities, Total | 0.124 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -22.107 | -7.171 | -12.337 | -4.183 | 1.727 |
Cash From Operating Activities | -10.597 | -6.603 | -4.021 | -3.017 | -2.729 |
Cash From Operating Activities | 0.038 | ||||
Amortization | 1.405 | ||||
Non-Cash Items | 11.949 | 1.018 | 8.073 | 1.38 | -5.924 |
Cash Interest Paid | 0 | ||||
Changes in Working Capital | -0.439 | -0.45 | 0.243 | -0.214 | 0.025 |
Cash From Investing Activities | -14.598 | -8.853 | -24.963 | 1.256 | -0.151 |
Capital Expenditures | -1.833 | -0.617 | -1.469 | -0.36 | -0.036 |
Other Investing Cash Flow Items, Total | -12.765 | -8.236 | -23.494 | 1.616 | -0.115 |
Cash From Financing Activities | -7.193 | 78.303 | 31.608 | 1.835 | 2.7 |
Financing Cash Flow Items | -22.026 | 0 | -0.106 | ||
Issuance (Retirement) of Stock, Net | 14.833 | 78.303 | 31.608 | 1.941 | 2.7 |
Net Change in Cash | -32.388 | 62.847 | 2.624 | 0.074 | -0.18 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -3.762 | -22.107 | -14.851 | -8.612 | -3.535 |
Cash From Operating Activities | -3.991 | -10.597 | -8.735 | -5.872 | -3.836 |
Non-Cash Items | 0.283 | 11.949 | 6.533 | 3.21 | -0.029 |
Changes in Working Capital | -0.519 | -0.439 | -0.417 | -0.47 | -0.272 |
Cash From Investing Activities | -18.711 | -14.598 | -15.959 | -15.278 | -10.078 |
Capital Expenditures | -0.361 | -1.833 | -0.525 | 0 | 0 |
Other Investing Cash Flow Items, Total | -18.35 | -12.765 | -15.434 | -15.278 | -10.078 |
Cash From Financing Activities | -0.939 | -7.193 | -6.372 | -5.621 | 18.991 |
Issuance (Retirement) of Stock, Net | -0.939 | 14.833 | 15.654 | 16.405 | 18.991 |
Net Change in Cash | -23.641 | -32.388 | -31.066 | -26.771 | 5.077 |
Financing Cash Flow Items | -22.026 | -22.026 | -22.026 | ||
Cash From Operating Activities | 0.007 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Dominari Holdings Inc. Company profile
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Alkido Pharma Inc.Incorporated and changed its name toDominari Holding Inc. in December 2022.Industry: | Biotechnology & Medical Research (NEC) |
One Rockefeller Plaza, 11Th Floor
NEW YORK
NEW YORK 10020
US
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com